TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04892069
Drug: Insulin Degludec/Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: All patients have been treated at the discretion of the treating physician in accordance with the Ryzodeg® label in Lebanon. Decision to initiate treatment with commercially available Ryzodeg® has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study.
Study: NCT04559230
Drug: Sacituzumab Govitecan
Normalized name: sacituzumab govitecan
DrugBank: Sacituzumab govitecan (DB12893)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sacituzumab Govitecan will be administered by IV infusion over 3 hours for first administration and over 1 hour if tolerated. Subjects will be allowed to continue treatment until they have evidence of significant treatment-related toxicity or progressive disease.
Study: NCT05514041
Drug: Varenicline solution
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: OC-01 nasal spray 0.03 mg
Study: NCT05514041
Drug: Placebo nasal spray (OC-01 Vehicle Nasal Spray)
Normalized name: OCE-205
DrugBank: OCE-205 (DB17617)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo nasal spray (OC-01 Vehicle Nasal Spray)
Study: NCT05062759
Drug: Tezepelumab
Normalized name: Tezepelumab
DrugBank: Tezepelumab (DB15090)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 210 mg SC injection Q4W.
Study: NCT06386146
Drug: JAB-30355
Normalized name: JAB-3068
DrugBank: JAB-3068 (DB17131)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT05043740
Drug: Repatha or Praluent
Normalized name: Repatha
DrugBank: Evolocumab (DB09303)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Evolocumab (Repatha®) 140 mg or Alirocumab (Praluent) 75mg every two weeks, first subcutaneous injection at the time of randomization, followings during 12 months
Study: NCT04718922
Drug: Chlorhexidine Gluconate 0.12 % Mouthwash
Normalized name: chlorhexidine gluconate 0.12 % Mouthwash
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intervention with chlorhexidine mouthrinse will be performed approximately 10 min before the start of EBUS-TBNA
Study: NCT06293742
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam will be administered orally.
Study: NCT06293742
Drug: Digoxin
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Digoxin will be administered orally.
Study: NCT06293742
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin will be administered orally.
Study: NCT04752371
Drug: Camoteskimab (CERC-007, AVTX-007, AEVI-007)
Normalized name: CERCIS SILIQUASTRUM WHOLE
DrugBank: Camoteskimab (DB18876)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) Infusion
Study: NCT04738292
Drug: Onapristone
Normalized name: Onapristone
DrugBank: Onapristone (DB12637)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Onapristone is a type I antiprogestin which prevents the PgR from dimerizing and blocks ligand induced protein kinase-mediated phosphorylation of the PgR.
Study: NCT04738292
Drug: Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fulvestrant binds, blocks and degrades the ER, completely inhibiting ER signaling.
Study: NCT05343325
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tislelizumab: 200 mg D1, Q3W for two cycles. Albumin-bound paclitaxel: 100mg/m2, D1, D8, D15, Q3W for two cycles. Cisplatin: 25mg/m2, D1, D8, D15, Q3W for two cycles.
Study: NCT05253495
Drug: DOC Group C
Normalized name: meningococcal group C polysaccharide
DrugBank: Meningococcal polysaccharide vaccine group C (DB13890)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cyclophosphamide x 1, dexamethasone x 5; vincristine x1; IT triples x 3
Study: NCT00000638
Drug: Isoniazid
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000638
Drug: Pyrazinamide
Normalized name: Pyrazinamide
DrugBank: Pyrazinamide (DB00339)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05253495
Drug: Pv-R CYVE-MTX 1 and 2
Normalized name: MTX
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Polatuzumab Vedotin x 1; Rituximab x 1; Cytarabine x 5; Etoposide x4; high dose cytarabine x4; high dose methotrexate x 1 (only consolidation 1); IT triples x 2 (only 1 in consolidation 2)
Study: NCT05253495
Drug: MAD CP
Normalized name: methylcellulose (1500 CPS)
DrugBank: Methylcellulose (DB11228)
Approvals — FDA: no, EMA: no, PMDA: no
Description: dexamethasone x1; polatuzumab vedotin x 1; cyclophosphamide x 2; doxorubicin x 1; high dose methotrexate x 1; IT triples x 1
Study: NCT05253495
Drug: Pv-Cytarabine/etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: polatuzumab vedotin x 1; cytarabine x 5; etoposide x 3;
Study: NCT05253495
Drug: AD CP
Normalized name: methylcellulose (1500 CPS)
DrugBank: Methylcellulose (DB11228)
Approvals — FDA: no, EMA: no, PMDA: no
Description: polatuzumab vedotin x 1; cyclophosphamide x2; doxorubicin x 2;
Study: NCT05938140
Drug: Nirmatrelvir/ritonavir
Normalized name: NIRMATRELVIR/RITONAVIR
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paxlovid is an oral drug for the treatment of COVID-19. It is suitable for adults with mild to moderate COVID-19 patients with high risk factors for progression to severe disease.
Study: NCT05918718
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: assessment of the efficacy of Letrozole in treatment of ectopic pregnancy
Study: NCT04520490
Drug: Exenatide 2 mg [Bydureon]
Normalized name: exenatide 2 MG [Bydureon]
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly injections of active drug.
Study: NCT00000638
Drug: Rifampin
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05638282
Drug: Cendakimab
Normalized name: Cendakimab
DrugBank: Cendakimab (DB18427)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT05292092
Drug: Essential pro
Normalized name: Climara Pro
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients in whom treatment with (Essential Pro) has been attempted
Study: NCT05322252
Drug: Mifepristone
Normalized name: Mifepristone
DrugBank: Mifepristone (DB00834)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200mg orally
Study: NCT05322252
Drug: Misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Per clinician
Study: NCT05382143
Drug: Atosiban
Normalized name: atosiban
DrugBank: Atosiban (DB09059)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Pilot study
Study: NCT04582136
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: In the double-blinded phase, sirolimus 1.5mg/day plus SOC is administered throughout 24 weeks; in the open-label extension period, patients who opt to participate continue on sirolimus 1.5mg/day plus SOC for an additional 24 weeks.
Study: NCT05720637
Drug: SSRI
Normalized name: SSRI - Selective serotonin re-uptake inhibitor
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSRIs antidepressants, including fluoxetine, paroxetine, sertraline, citalopram, etc., will be administered at oral doses determined by the psychiatrist. Once daily for the duration of the trial.
Study: NCT06199076
Drug: Oxytocin nasal spray
Normalized name: oxytocin Nasal Spray
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The clinical trial is a phase II-study double-blind placebo-controlled study. The trial will have a parallel group cross-over design where subjects with alcohol use disorder versus healthy controls will administer a single dose of intranasal oxytocin versus placebo on two study visits 1-3 weeks apart.
Study: NCT06155994
Drug: 68Ga-DOTA-MGS5
Normalized name: 68Ga-DOTATATE
DrugBank: Dotatate gallium Ga-68 (DB13925)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous administration
Study: NCT06306339
Drug: Burfiralimab
Normalized name: Burfiralimab
DrugBank: Burfiralimab (DB18935)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Humanized monoclonal antibody.
Study: NCT04790539
Drug: SHR-1210
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-1210 is a humanized anti-PD-1 IgG4 monoclonal antibody
Study: NCT05619328
Drug: Vitamin B combination tablet
Normalized name: VITAMIN B
DrugBank: Cyanocobalamin (DB00115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once daily, with some liquid with or after a meal
Study: NCT04867928
Drug: Venetoclax+azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: subjects will receive venetoclax 400 mg orally QD on Days 1 - 28 plus azacitidine 75 mg/m2 SC or IV daily for 7 days. Cycle Length - 28 Days. . Subjects will continue treatment until subsequent alloSCT.
Study: NCT00016536
Drug: Naphthalene 2-sulfonate polymer
Normalized name: Naphthalene 2-sulfonate polymer
DrugBank: PRO 2000 (DB05385)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00016536
Drug: Carbopol polymer
Normalized name: Carbopol polymer
DrugBank: Carbopol 974P (DB05384)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05494528
Drug: Ropeginterferon alfa-2b
Normalized name: Ropeginterferon alfa-2b
DrugBank: Ropeginterferon alfa-2b (DB15119)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ropeginterferon alfa-2b 450 µg subcutaneous injection every two weeks
Study: NCT05494528
Drug: Entecavir
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Entecavir 0.5 mg once per day
Study: NCT04590118
Drug: it-hMSC
Normalized name: IT-139
DrugBank: IT-139 (DB17145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous infusion of it-hMSC for ischemic stroke patients
Study: NCT04530474
Drug: Ivermectin Pill
Normalized name: ivermectin Pill
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivermecin as a one-time dose
Study: NCT03567824
Drug: Magnesium L-lactate dihydrate
Normalized name: Magnesium L-lactate Dihydrate
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium L-lactate dihydrate 10 mEq extended release caplets
Study: NCT06402019
Drug: Dexmedetomidine in 0.9 % NaCl 20 Mcg/5 mL (4 Mcg/mL) INTRAVEN SYRINGE (ML)
Normalized name: dexmedetomidine in 0.9 % NaCl 20 mcg/5 mL (4 mcg/mL) INTRAVEN SYRINGE (ML)
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Group went under multiple sessions of Dexmedetomidine infusion for 10 sessions; The infusion was provided under non-invasive monitoring for heart rate (HR) and mean arterial pressure (MAP). The infusion rate was adjusted to maintain HR in range of 60-80 beats/min and MAP in range of 65-75 mmHg.
Study: NCT00000739
Drug: Dapsone
Normalized name: Dapsone
DrugBank: Dapsone (DB00250)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06384573
Drug: lecanemab
Normalized name: Lecanemab
DrugBank: Lecanemab (DB14580)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously
Study: NCT05385432
Drug: Rabbit Anti thymocyte globulin (rATG)
Normalized name: Rabbit anti-human thymocyte globulin (rATG)
DrugBank: Rabbit (DB10415)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The infusion of rTAG (Thymoglobulin® (1.5mg/kg/day, maximum daily dose: 100 mg)) starts just after the randomization pre-operatively on a functional arteriovenous fistula or a high-flow venous catheter during 3 to 7 days until efficient tacrolimus level is obtained.
Study: NCT05385432
Drug: Basiliximab
Normalized name: Basiliximab
DrugBank: Basiliximab (DB00074)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Simulect® IV 40mg D0 and D4
Study: NCT01028313
Drug: Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 mg/kg/day PO continuously
Study: NCT06598449
Drug: fenfluramine
Normalized name: fenfluramine
DrugBank: Fenfluramine (DB00574)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clear, cherry flavored oral solution
Study: NCT06403709
Drug: Irinotecan, Trifluridine/tipiracil (TAS-102) plus Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: These patients received an intravenous infusion of irinotecan (150mg/m2 on day 1) plus bevacizumab (5 mg/kg on day 1) and an oral administration of TAS-102(30 mg/m2 given bid on days 1-5), repeated every 14 days.
Study: NCT06440135
Drug: Ziftomenib
Normalized name: Ziftomenib
DrugBank: Ziftomenib (DB17171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taken orally once per day
Study: NCT03503058
Drug: Chloroquine chemoprophylaxis alone
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Loading Dose: 10 mg/kg of CQ base (will be orally administered as a single loading dose to the participant by the study staff via directly observed therapy on NS Day -2.~Weekly Dose: Subsequent doses of maintenance dose CQ (5 mg/kg CQ base) will be given weekly as a single dose, with the last dose 5 days after the last dose of NS.
Study: NCT06433947
Drug: OPN-6602
Normalized name: anti-Tlr2 monoclonal antibody OPN-305
DrugBank: Tomaralimab (DB15415)
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally active, small molecule inhibitor of EP300 and CBP bromodomain; dosed daily
Study: NCT06433947
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Synthetic glucocorticoid; 40 mg Days 1, 8, 15 of each cycle
Study: NCT06270108
Drug: Riluzole
Normalized name: Riluzole
DrugBank: Riluzole (DB00740)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50mg twice daily (100mg total daily) for 56 days.
Study: NCT06326736
Drug: Camrelizumab
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camrelizumab will be administered 6 weeks post-tumor resection.
Study: NCT06326736
Drug: Gemcitabine+Abraxane
Normalized name: Abraxane
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine+Abraxane regimen will be administered 21 weeks post-tumor resection.
Study: NCT06277674
Drug: Cadonilimab plus Pemetrexed and Anlotinib
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cadonilimab was administered intravenously at a dose of 10 mg/kg every 3 weeks. Pemetrexed was administered intravenously at a dose of 500 mg/m² every 3 weeks Anlotinib was taken at doses of 10mg orally once daily for two weeks on a one-week-off schedule.
Study: NCT05550350
Drug: Dexycu
Normalized name: Dexycu
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 103.4 mcg/mcl dexamethasone: equivalent dexamethasone dose: 517 mcg
Study: NCT04958876
Drug: Naltrexone immediate release oral capsules
Normalized name: morphine / naltrexone Extended Release Oral Capsule
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral capsule once daily
Study: NCT05130047
Drug: Aldafermin
Normalized name: Aldafermin
DrugBank: Aldafermin (DB16086)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg solution
Study: NCT00561366
Drug: Arimoclomol
Normalized name: arimoclomol
DrugBank: Arimoclomol (DB05025)
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsule, 400 mg t.i.d.
Study: NCT06000137
Drug: Dezocine
Normalized name: DEZOCINE
DrugBank: Dezocine (DB01209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dezocine for patient-controlled analgesia
Study: NCT06000137
Drug: Granisetron Injection
Normalized name: granisetron Injection
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: granisetron has antiemetic function.
Study: NCT02354612
Drug: TRC105
Normalized name: IMMUNOGLOBULIN G1, ANTI-(HUMAN ENDOGLIN) (HUMAN-MUS MUSCULUS MONOCLONAL TRC105 HEAVY CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL TRC105 .KAPPA.-CHAIN, DIMER
DrugBank: Carotuximab (DB06322)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02354612
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: companion therapy selection depends on companion therapy used in the parent study
Study: NCT02354612
Drug: Axitinib
Normalized name: Axitinib
DrugBank: Axitinib (DB06626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: companion therapy selection depends on companion therapy used in the parent study
Study: NCT02354612
Drug: Pazopanib
Normalized name: Pazopanib
DrugBank: Pazopanib (DB06589)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: companion therapy selection depends on companion therapy used in the parent study
Study: NCT06248099
Drug: Nebivolol-Test product
Normalized name: nebivolol Oral Product
DrugBank: Nebivolol (DB04861)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Test-Product: Nebivolol tablets 5 mg Manufactured by: Hetero Labs Limited, India
Study: NCT06248099
Drug: Nebivolol-Reference product
Normalized name: nebivolol Oral Product
DrugBank: Nebivolol (DB04861)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reference-product: Nebilet tablets 5 mg Manufactured by: BERLIN CHEMIE AG, Germany
Study: NCT04026880
Drug: Testosterone Enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg testosterone enanthate administered by intramuscular injection weekly for 12 weeks
Study: NCT05189873
Drug: HRT
Normalized name: femhrt
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In the HRT group, from the second day of the cycle, the participant receives 2 mg of estradiol daily and this drug is increased to 6 mg per day in three days.Ten days later, they undergo vaginal ultrasound to check the thickness of the endometrium. If the thickness of the endometrium is greater than 8 mm, inject able progesterone is prescribed and the patient is a candidate for FET transfer. If the thickness is less than 7 mm, it is necessary to increase the dose of estradiol and continue treatment with it. The patient undergoes vaginal ultrasound every three days and if the desired thickness does not reach 21 days after the start of the cycle, the cycle is canceled
Study: NCT05562869
Drug: Belatacept 250 Milligram Intravenous Powder for Solution
DrugBank: Belatacept (DB06681)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Phase 1 (from 3 to 12 months post transplantation): conversion to belatacept (IV, 5mg/Kg days 1, 15,30, 45, 60 then every months) and CNI withdrawal.~Phase 2 (from 12 to 18 months post transplantation) : belatacept arrest and CNI resumption (tacrolimus target 6 ng/ml)
Study: NCT05525260
Drug: Limonene capsule
DrugBank: Limonene, (+/-)- (DB19146)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citrus foods rich in D-limonene were forbiden 2 days before taking the drug (washout period), which was maintained after taking the drug.Limonene capsules group and placebo group were used for treatment. The random number is generated by the central randomization system. All the recruiters were divided into placebo control group and limonene capsule administration group. The numbers will be assigned according to random numbers. In this study, qualified subjects were randomly assigned to the treatment group and the placebo control group at a ratio of 1:1. The drug was administered for 12 weeks, 3 times a day, 5 capsules each time.
Study: NCT05525260
Drug: Limonene capsules(Placebo)
DrugBank: Limonene, (+/-)- (DB19146)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Limonene capsules(Placebo)
Study: NCT05866068
Drug: Clomiphene
Normalized name: Clomiphene
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate 100mg daily during IVF stimulation
Study: NCT05486416
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol for induction of general anesthesia
Study: NCT03866499
Drug: BPI-7711
Normalized name: BPI-3016
DrugBank: BPI-3016 (DB15158)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180 mg, oral, QD
Study: NCT03866499
Drug: Gefitinib
Normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 250 mg, oral, QD
Study: NCT05416073
Drug: Esketamine
Normalized name: ESKETAMINE
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: PCIA formula：100ml analgesic solution was prepared by adding 2.5 mg/kg Esketamine and 8mg ondansetron into normal saline.~30min before TACE treatment, the first dose of 2ml was slowly injected intravenously. No obvious adverse reactions were observed for 10min. After that, the intravenous analgesia pump was started. Parameter setting of intravenous analgesia pump: the total volume is 100ml; The duration is 2ml / h; The single dose is 2ml each time; The limit quantity is 10ml / h; The locking time was 10min and the analgesia lasted for 48h.~The target value of analgesia in this study was NRS (Numerical Rating Scale)\< 4; If NRS ≥ 4, when the effect is still poor after adding drugs by pressing the analgesic pump, the investigators will give the remedial drug(dolantin 50mg im st) according to the patient's condition.
Study: NCT05775796
Drug: Serplulimab and Chemotherapy
Normalized name: cytarabine and daunorubicin
DrugBank: Serplulimab (DB17451)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serplulimab+Paclitaxel+Cisplatin/Carboplatin Serplulimab+Pemetrexed+Cisplatin/Carboplatin
Study: NCT05102721
Drug: Avelumab and Pepinemab
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV Infusions every two weeks.
Study: NCT00344695
Drug: bupropion SR
Normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05443646
Drug: HLX10
Normalized name: Immunoglobulin g4 (228-proline), anti-(human programmed cell death protein 1) (human-mus musculus monoclonal hlx10 .gamma.4-chain), disulfide with human-mus musculus monoclonal hlx10 .kappa.-chain, dimer
DrugBank: Serplulimab (DB17451)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HLX10 is an innovative monoclonal antibody targeting PD-1，developed by Shanghai Henlius Biotech, Inc.~300mg Q3W
Study: NCT04021550
Drug: Telmisartan 80mg
Normalized name: TELMISARTAN 80MG TAB
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects in this group will receive 80mg/day of Telmisartan (an angiotensin receptor blocker). Treatments will be administered in pre-packaged blister packages. Subjects will take Telmisartan once per day for 6 weeks.
Study: NCT06070636
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 12 mg (or 8 mg) once daily (QD) oral dosing.
Study: NCT06070636
Drug: Sintilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg intravenously every 32 weeks